Legal and Regulatory Settlement

Glenmark Pharmaceuticals Enters $29.63 Million Settlement in US Antitrust Litigation

NSE

glenmark

BSE

532296

Glenmark Pharmaceuticals Limited announced that its US subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to a settlement with multiple US state attorneys general in ongoing antitrust and generic drug pricing litigation. The settlement amount stands at $29.628 million payable over five years, with the company clarifying that no admission of wrongdoing or liability has been made.

PRICE-SENSITIVE TRIGGER

Event: Settlement Agreement in US Antitrust Litigation

Type: Legal and Regulatory Settlement

Impact: Neutral

Immediate Effect: Glenmark USA has agreed to settle litigation claims relating to alleged anti-competitive conduct in the US generic pharmaceutical market, while the company stated that the financial impact has already been fully provided for in its books.

Key Metrics:

Settlement Amount:
- USD 29.628 million
- Payable over 5 years
Provisioning Status:
- Entire settlement amount already provided in company financials
Payment Structure:
- Annual instalments over five years
Financial Impact:
- Company stated no significant impact on financial position

Highlight:

Glenmark confirmed that the full settlement liability has already been accounted for, limiting incremental financial impact.

What Happened ?

Glenmark Pharmaceuticals Limited disclosed that its US subsidiary, Glenmark Pharmaceuticals Inc., USA (“Glenmark USA”), has agreed to enter into a settlement arrangement with multiple US state attorneys general in relation to ongoing antitrust and consumer protection litigation in the United States.

The litigation pertains to allegations involving:

Generic drug pricing
Market allocation
Anti-competitive conduct

The lawsuits include:

Class action proceedings
Direct purchaser claims
End-payer claims
Indirect purchaser claims
Private direct-action lawsuits
Claims initiated by 46 US state attorneys general

The proceedings were consolidated within US district courts, with certain complaints transferred to the District of Connecticut during 2024.

Glenmark USA stated that:

It denies all allegations
The settlement does not constitute admission of liability
The agreement aims to avoid uncertainty and resolve the dispute

The settlement remains subject to court approval overseeing the litigation proceedings.

Key Details

Settlement and Litigation Details:

Glenmark USA agreed to a settlement amount of USD 29.628 million.
The settlement will be paid through annual instalments across five years.
The litigation relates to alleged violations of federal antitrust laws in the pricing of generic pharmaceutical products.
Plaintiffs alleged:
- Drug-specific conspiracies
- Broad anti-competitive coordination among generic drug manufacturers
Glenmark USA and other defendants have strongly denied all allegations.
The company emphasized that the settlement:
- Avoids prolonged litigation uncertainty
- Does not imply wrongdoing
- Does not constitute admission of guilt or illegality
The entire settlement obligation has already been recognized in the company’s financial statements.
The settlement remains subject to judicial approval by the overseeing court.

Note:

The company clarified that legal settlements are common within the pharmaceutical industry and stated that the settlement is intended to resolve uncertainty around prolonged litigation exposure.

Risk Analysis

Summary:

Although Glenmark stated that the settlement will not materially impact financials, the litigation highlights ongoing regulatory and legal scrutiny in the US generic pharmaceutical market.

Key Risks:

Continued regulatory scrutiny in the US generics industry may create future compliance risks.
Antitrust investigations and litigation could impact reputation within regulated markets.
Additional legal claims or industry-wide investigations cannot be ruled out.
Settlement-related disclosures may increase investor sensitivity toward US operations.
Court approval remains pending for the settlement agreement.
Extended legal disputes in regulated pharmaceutical markets can increase compliance and legal costs.

Worst Case Scenario:

Any escalation of antitrust scrutiny, additional lawsuits, or adverse judicial findings in related matters could increase legal liabilities and impact investor confidence in Glenmark’s US generics business.

Risk Level: Medium

Company Commentary

Glenmark stated that the settlement is intended to resolve litigation uncertainty.
The company reiterated that Glenmark USA denies each and every allegation made against it.
Management clarified that the settlement does not represent any admission of liability, wrongdoing, or illegality.
Glenmark confirmed that the entire settlement amount has already been fully provided for in its financial statements.
The company stated that the settlement will not have a significant impact on its financial position.

Official Exchange Filing: Glenmark Pharmaceuticals Limited